Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q4 FY21 results · Jan–Mar 2021
Neuland Laboratories reported revenue from operations of ₹244.70 crore (up 27.7% from Q4 FY20) and net profit of ₹17.29 crore for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 244.70 | 191.64 | +27.7% | 245.39 | −0.3% |
| Other income | 14.60 | 1.78 | +721.8% | 0.20 | 75x |
| Total income | 259.30 | 193.42 | +34.1% | 245.59 | +5.6% |
| Profit before tax | 24.39 | 17.20 | +41.8% | 31.95 | −23.7% |
| Net profit for the period | 17.29 | (9.30) | Turned profit | 26.74 | −35.3% |
| EPS, basic (₹) | 13.48 | (7.25) | Turned profit | 20.84 | −35.3% |
| Net margin (%) | 7.1 | -4.9 | 10.9 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 244.70 | 191.87 | +27.5% | 245.39 | −0.3% |
| Other income | 14.60 | 1.78 | +721.9% | 0.20 | 75x |
| Total income | 259.30 | 193.64 | +33.9% | 245.59 | +5.6% |
| Profit before tax | 24.32 | 17.08 | +42.4% | 31.86 | −23.7% |
| Net profit for the period | 17.23 | (9.35) | Turned profit | 26.67 | −35.4% |
| EPS, basic (₹) | 13.43 | (7.29) | Turned profit | 20.79 | −35.4% |
| Net margin (%) | 7.0 | -4.9 | 10.9 |
Consolidated
- Filed with BSE
- 11 May 2021, 17:36 IST
- Board meeting
- 11 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 May 2021, 17:36 IST
- Board meeting
- 11 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE